跳轉至內容
Merck
全部照片(1)

Key Documents

View All Documentation

L-907

Supelco

氯甲西泮标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C16H12Cl2N2O2
CAS號碼:
848-75-9
分子量：:
335.18
EC號碼:
200-659-6
MDL號碼:
MFCD00058578
分類程式碼代碼:
41116107
PubChem物質ID:
329817667
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

−20°C

SMILES 字串

CN1C(=O)C(O)N=C(c2ccccc2Cl)c3cc(Cl)ccc13

InChI

1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3

InChI 密鑰

FJIKWRGCXUCUIG-UHFFFAOYSA-N

一般說明

Lormetazepam is a benzodiazepine with sedative-hypnotic, anxiolytic, anticonvulsant, and muscle relaxant effects. This certified solution standard is suitable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Lormetazepam is sold under trade names Loramet and Noctamid for treatment of insomnia.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

產品號碼
描述
訂價

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 1

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Hervé Allain et al.
European journal of clinical pharmacology, 59(3), 179-188 (2003-05-21)
In elderly patients, both falls and impaired memory are considerable medical problems. Hypnotics, which are frequently administered to this patient group for the treatment of insomnia, should ideally not impair equilibrium or memory functions. This double-blind, randomised, four-way, cross-over study
Francesco Benedetti et al.
International clinical psychopharmacology, 19(5), 311-317 (2004-08-04)
Benzodiazepines can shift the phase of circadian rhythms in mammalian species, but few data are available on their phase-response effects in humans, and on possible links between timing of administration and hypnotic efficacy. Using a placebo-controlled, cross-over design, we evaluated
Inga Katofsky et al.
Sleep medicine, 13(5), 463-468 (2012-02-22)
This study was conducted to evaluate the effectiveness of a cognitive behavioral self-help program (SHP) in combination with pharmacotherapy in patients with primary insomnia in general practice. Patients were recruited from 31 general practitioners (GPs) in the Hamburg area, who
E Nováková
Soudni lekarstvi, 43(1), 2-4 (1998-04-30)
The determination of benzodiazepine derivatives lorazepam and lormetazepam in urine is based on detection of their metabolites 2-amino-2',5-dichlorobenzophenone and 2-methylamino-2'5-dichlorbenzophenone in hydrolyzed urine. Both substances are structurally very similar to the metabolites of diazepam 2-amino-5-chlorbenzophenone and 2-methylamino-5-chlorbenzophenone and their mobility
Patrick Lemmer et al.
Journal of analytical toxicology, 31(4), 224-226 (2007-06-09)
Lormetazepam (Loramet is a benzodiazepine mainly used as an hypnotic to treat insomnia. Lorazepam (Temesta) is used as an anxiolytic, tranquilizer, sedative, and anticonvulsant, and it is the major metabolite of lormetazepam. In this study, we designed a method to
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務